Categories Analysis, Earnings, Health Care
Earnings preview Q4: Amyris likely to benefit from the new cannabinoid deal
Renewables product company Amyris (AMRS) is set to report its fourth quarter and full-year 2018 results on Monday, March 18 after the market closes. Analysts expect the company to report earnings of $0.44 per share on revenue of $98.52 million for the quarter ended December 31, 2018. On Friday, Amyris shares, which opened at $4.16 in the morning, closed down 5.3% at $3.93.
In the fourth quarter of 2017, the company reported GAAP loss of $0.17 per share and non-GAAP loss of $0.61 per share on revenue of $80.6 million. Amyris had projected 2018 revenue to be in the range of $185 million to $195 million.
Check out Amyris’ previous quarter earnings calls audios here
For the third quarter ended September 30, 2018, non-GAAP loss per share stood at 63 cents and GAAP loss per share was $1.67 on revenue of $14.9 million.
The Emeryville, California-based firm’s recent cannabis deal that is valued up to $255 million with a confidential partner is expected to boost the company’s bottom and top-line numbers. A final definitive agreement is expected by the end of March with commercialization of products expected within the next 18-24 months assuming appropriate regulatory approvals. Amyris stock surged 73% on this deal announcement.
The undisclosed partner is estimated to provide initially lab-based and later commercial scale milestone cash payments in tranches for the development and scaling of technology to produce CBD. In return, the partner will be granted a license to commercialize these products.
The recent boom in the US cannabis market is expected to positively impact Amyris’ performance in the future.
At December-end, Amyris signed a long-term agreement with Xinfu of China for a significant initial payment and a long-term minimum annual share of an existing nutritional product royalty arrangement. The company also received FDA’s acceptance for its zero-calorie sweetner in December 2018.
Canada-based marijuana giant Tilray (TLRY) is also expected to publish its quarterly earnings results on Monday after the market close.
Amyris stock had gained 18% so far this year, while it declined 4% in the past three months period.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on